Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- Prevalence and risk-factors for SARS-CoV-2 infection
研究概览
简要总结
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent
排除标准
- •age under 18 years
结局指标
主要结局
Prevalence and risk-factors for SARS-CoV-2 infection
时间窗: inclusion during 4 months
Prevalence and risk-factors for SARS-CoV-2 infection
Prevalence and risk-factors for COVID-19
时间窗: inclusion during 4 months
Prevalence and risk-factors for COVID-19
次要结局
- Durability of IgG positivity(12 months)